# Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma

> **NCT07747935** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **ReBio Pharma** · enrollment: 30 (estimated)

## Conditions studied

- Uveal Melanoma

## Interventions

- **DRUG:** RBP-01

## Key facts

- **NCT ID:** NCT07747935
- **Lead sponsor:** ReBio Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07747935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07747935, "Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07747935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*